Thrombolytic therapy for deep venous thrombosis?
We present the case of a man bedridden by deep venous thrombosis who was given intraclot instillations of recombinant tissue plasminogen activator with remarkable improvement. Although such aggressive treatment may be justified in severe cases, the role for thrombolytic agents for less symptomatic deep venous thrombosis is undefined. We discuss the question of when thrombolytic therapy should be considered. However, proper clinical trials are needed before firm recommendations can be made.
Horne
M K
MK
Clinical Pathology Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA. mhorne@nih.gov
Chang
R
R
D000328:Adult; D003110:Colonic Neoplasms / Q000150:complications / Q000473:pathology; D003657:Decision Making; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications / Q000556:secondary; D008297:Male; D011152:Popliteal Vein; D011859:Radiography; D012306:Risk; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014682:Vena Cava, Inferior; D020246:Venous Thrombosis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator